Triple therapy using direct-acting agents for recurrent hepatitis C after liver transplantation: A single-center experience

Toru Ikegami, Tomoharu Yoshizumi, Yuji Soejima, Norifumi Harimoto, shinji itoh, kazuki takeishi, H. Uchiyama, H. Kawanaka, Y. I. Yamashita, E. Tsujita, Noboru Harada, Eiji Oki, Hiroshi Saeki, Yasue Kimura, K. Shirabe, Yoshihiko Maehara

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background Hepatitis C viral graft reinfection is almost a universal event after liver transplantation with consequent disease progression. Methods We applied triple therapy (n = 21) with the use of telaprevir (TVR; n = 12) or simeprevir (SVR; n = 9). Results TVR was given at the dose 1,500 mg daily (n = 11) with reduced dose of cyclosporine at 25% to 50%, and SVR was given at the dose 100 mg daily with unadjusted cyclosporine, followed by 12 weeks of dual therapy. The early viral response was achieved in 91.7% (n = 11), end of treatment response rate was 91.7% (n = 11), and sustained viral response rate was 83.3% (n = 10) in the TVR group, and respective rates were 88.9% (n = 8), 77.8% (n = 7), and 77.8% (n = 7) in the SVR group. Although granulocyte colony-stimulating factor was not given in the patients with triple therapy, blood transfusion was performed in 7 cases (58.3%) in the TVR group and 1 case (11.1%) in the SVR group. Interferon-mediated graft dysfunction was observed in 4 cases (33.3%) in the TVR group and 3 cases (33.3%) in the SVR group, respectively. The cumulative viral clearance rates in triple (n = 21) and dual (n = 105) therapy were 95.0% and 18.1% at 12 weeks, and 95.0% and 40.0%, respectively, at 24 weeks (P <.01). Conclusions Although careful monitoring for possible adverse events is required during treatment, triple therapy with the use of direct-acting agents are very effective in treating hepatitis C after liver transplantation.

Original languageEnglish
Pages (from-to)730-732
Number of pages3
JournalTransplantation Proceedings
Volume47
Issue number3
DOIs
Publication statusPublished - Apr 1 2015

Fingerprint

Hepatitis C
Liver Transplantation
Therapeutics
Cyclosporine
Transplants
Granulocyte Colony-Stimulating Factor
Blood Transfusion
Interferons
Disease Progression

All Science Journal Classification (ASJC) codes

  • Surgery
  • Transplantation

Cite this

Triple therapy using direct-acting agents for recurrent hepatitis C after liver transplantation : A single-center experience. / Ikegami, Toru; Yoshizumi, Tomoharu; Soejima, Yuji; Harimoto, Norifumi; itoh, shinji; takeishi, kazuki; Uchiyama, H.; Kawanaka, H.; Yamashita, Y. I.; Tsujita, E.; Harada, Noboru; Oki, Eiji; Saeki, Hiroshi; Kimura, Yasue; Shirabe, K.; Maehara, Yoshihiko.

In: Transplantation Proceedings, Vol. 47, No. 3, 01.04.2015, p. 730-732.

Research output: Contribution to journalArticle

Ikegami, Toru ; Yoshizumi, Tomoharu ; Soejima, Yuji ; Harimoto, Norifumi ; itoh, shinji ; takeishi, kazuki ; Uchiyama, H. ; Kawanaka, H. ; Yamashita, Y. I. ; Tsujita, E. ; Harada, Noboru ; Oki, Eiji ; Saeki, Hiroshi ; Kimura, Yasue ; Shirabe, K. ; Maehara, Yoshihiko. / Triple therapy using direct-acting agents for recurrent hepatitis C after liver transplantation : A single-center experience. In: Transplantation Proceedings. 2015 ; Vol. 47, No. 3. pp. 730-732.
@article{ed780eff7f24427a8905a9ab292bc2c8,
title = "Triple therapy using direct-acting agents for recurrent hepatitis C after liver transplantation: A single-center experience",
abstract = "Background Hepatitis C viral graft reinfection is almost a universal event after liver transplantation with consequent disease progression. Methods We applied triple therapy (n = 21) with the use of telaprevir (TVR; n = 12) or simeprevir (SVR; n = 9). Results TVR was given at the dose 1,500 mg daily (n = 11) with reduced dose of cyclosporine at 25{\%} to 50{\%}, and SVR was given at the dose 100 mg daily with unadjusted cyclosporine, followed by 12 weeks of dual therapy. The early viral response was achieved in 91.7{\%} (n = 11), end of treatment response rate was 91.7{\%} (n = 11), and sustained viral response rate was 83.3{\%} (n = 10) in the TVR group, and respective rates were 88.9{\%} (n = 8), 77.8{\%} (n = 7), and 77.8{\%} (n = 7) in the SVR group. Although granulocyte colony-stimulating factor was not given in the patients with triple therapy, blood transfusion was performed in 7 cases (58.3{\%}) in the TVR group and 1 case (11.1{\%}) in the SVR group. Interferon-mediated graft dysfunction was observed in 4 cases (33.3{\%}) in the TVR group and 3 cases (33.3{\%}) in the SVR group, respectively. The cumulative viral clearance rates in triple (n = 21) and dual (n = 105) therapy were 95.0{\%} and 18.1{\%} at 12 weeks, and 95.0{\%} and 40.0{\%}, respectively, at 24 weeks (P <.01). Conclusions Although careful monitoring for possible adverse events is required during treatment, triple therapy with the use of direct-acting agents are very effective in treating hepatitis C after liver transplantation.",
author = "Toru Ikegami and Tomoharu Yoshizumi and Yuji Soejima and Norifumi Harimoto and shinji itoh and kazuki takeishi and H. Uchiyama and H. Kawanaka and Yamashita, {Y. I.} and E. Tsujita and Noboru Harada and Eiji Oki and Hiroshi Saeki and Yasue Kimura and K. Shirabe and Yoshihiko Maehara",
year = "2015",
month = "4",
day = "1",
doi = "10.1016/j.transproceed.2014.10.058",
language = "English",
volume = "47",
pages = "730--732",
journal = "Transplantation Proceedings",
issn = "0041-1345",
publisher = "Elsevier USA",
number = "3",

}

TY - JOUR

T1 - Triple therapy using direct-acting agents for recurrent hepatitis C after liver transplantation

T2 - A single-center experience

AU - Ikegami, Toru

AU - Yoshizumi, Tomoharu

AU - Soejima, Yuji

AU - Harimoto, Norifumi

AU - itoh, shinji

AU - takeishi, kazuki

AU - Uchiyama, H.

AU - Kawanaka, H.

AU - Yamashita, Y. I.

AU - Tsujita, E.

AU - Harada, Noboru

AU - Oki, Eiji

AU - Saeki, Hiroshi

AU - Kimura, Yasue

AU - Shirabe, K.

AU - Maehara, Yoshihiko

PY - 2015/4/1

Y1 - 2015/4/1

N2 - Background Hepatitis C viral graft reinfection is almost a universal event after liver transplantation with consequent disease progression. Methods We applied triple therapy (n = 21) with the use of telaprevir (TVR; n = 12) or simeprevir (SVR; n = 9). Results TVR was given at the dose 1,500 mg daily (n = 11) with reduced dose of cyclosporine at 25% to 50%, and SVR was given at the dose 100 mg daily with unadjusted cyclosporine, followed by 12 weeks of dual therapy. The early viral response was achieved in 91.7% (n = 11), end of treatment response rate was 91.7% (n = 11), and sustained viral response rate was 83.3% (n = 10) in the TVR group, and respective rates were 88.9% (n = 8), 77.8% (n = 7), and 77.8% (n = 7) in the SVR group. Although granulocyte colony-stimulating factor was not given in the patients with triple therapy, blood transfusion was performed in 7 cases (58.3%) in the TVR group and 1 case (11.1%) in the SVR group. Interferon-mediated graft dysfunction was observed in 4 cases (33.3%) in the TVR group and 3 cases (33.3%) in the SVR group, respectively. The cumulative viral clearance rates in triple (n = 21) and dual (n = 105) therapy were 95.0% and 18.1% at 12 weeks, and 95.0% and 40.0%, respectively, at 24 weeks (P <.01). Conclusions Although careful monitoring for possible adverse events is required during treatment, triple therapy with the use of direct-acting agents are very effective in treating hepatitis C after liver transplantation.

AB - Background Hepatitis C viral graft reinfection is almost a universal event after liver transplantation with consequent disease progression. Methods We applied triple therapy (n = 21) with the use of telaprevir (TVR; n = 12) or simeprevir (SVR; n = 9). Results TVR was given at the dose 1,500 mg daily (n = 11) with reduced dose of cyclosporine at 25% to 50%, and SVR was given at the dose 100 mg daily with unadjusted cyclosporine, followed by 12 weeks of dual therapy. The early viral response was achieved in 91.7% (n = 11), end of treatment response rate was 91.7% (n = 11), and sustained viral response rate was 83.3% (n = 10) in the TVR group, and respective rates were 88.9% (n = 8), 77.8% (n = 7), and 77.8% (n = 7) in the SVR group. Although granulocyte colony-stimulating factor was not given in the patients with triple therapy, blood transfusion was performed in 7 cases (58.3%) in the TVR group and 1 case (11.1%) in the SVR group. Interferon-mediated graft dysfunction was observed in 4 cases (33.3%) in the TVR group and 3 cases (33.3%) in the SVR group, respectively. The cumulative viral clearance rates in triple (n = 21) and dual (n = 105) therapy were 95.0% and 18.1% at 12 weeks, and 95.0% and 40.0%, respectively, at 24 weeks (P <.01). Conclusions Although careful monitoring for possible adverse events is required during treatment, triple therapy with the use of direct-acting agents are very effective in treating hepatitis C after liver transplantation.

UR - http://www.scopus.com/inward/record.url?scp=84928345067&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928345067&partnerID=8YFLogxK

U2 - 10.1016/j.transproceed.2014.10.058

DO - 10.1016/j.transproceed.2014.10.058

M3 - Article

C2 - 25891720

AN - SCOPUS:84928345067

VL - 47

SP - 730

EP - 732

JO - Transplantation Proceedings

JF - Transplantation Proceedings

SN - 0041-1345

IS - 3

ER -